RetinAI attends OIS Retina Innovation Summit and ASRS 2022 Annual Meeting from July 13th to 16th in New York

Latest press releases

RetinAI announces multi-year software license and services agreement for RetinAI Discovery® UNITY platform

RetinAI announces a multi-year license and services agreement with Novartis AG (“Novartis”) for its Discovery® UNITY platform. Discovery UNITY is RetinAI’s top of the line enterprise-wide solution to aggregate imaging data for global organizations, including data from clinical and real-world evidence studies, with AI that can be applied to improve understanding of patient populations and outcomes at scale.

RetinAI receives FDA Clearance for Discovery, our medical image & data management platform for Ophthalmology

RetinAI today announces U.S. Food and Drug Administration (FDA) 510(k) clearance of RetinAI Discovery®, the company’s image and data management platform for next-level interoperability across the clinical and clinical study ecosystems in Ophthalmology.

RetinAI attends ARVO 2022

RetinAI will attend the ARVO 2022 Annual Meeting in Denver, Colorado, from May 1st to 4th at the Colorado Convention Center. RetinAI will showcase its innovative data management and AI analysis solutions to optimize and simplify clinical development workflows for stakeholders in pharma, research and clinics. ARVO attendees who visit RetinAI at Booth #3008 will benefit from learning and seeing live demos on RetinAI Discovery for clinical studies, Discovery UNITY and RetinAI's Disease Evaluation Apps.

RetinAI highlights Geographic Atrophy research with models available for analysis to enable the right decision sooner during clinical studies

RetinAI is pleased to share research findings from three published papers in Geographic Atrophy (GA). In collaboration with the Department of Ophthalmology at the University of Lausanne, Jules-Gonin Hospital, researchers at RetinAI developed a model for predicting atrophy risk in patients with non-exudative age-related macular degeneration (AMD).

Latest updates

Machine learning can predict anti-VEGF treatment demand in a Treat-and-Extend regimen for patients with nAMD, DME and RVO associated ME

2 new Posters in ARVO 2021 Virtual

We are very excited of our team and collaborators presenting 2 posters in ARVO 2021! One Poster on 'Longitudinal analysis of Retinal Pigment Epithelium Atrophy progression using an automated segmentation algorithm' providing segmentation analysis over 5 years using deep learning,
and a poster on 'Automated fovea and optic disc detection in the presence of occlusions in Fundus SLO Images'.

New publication on TVST - Automated quantification of pathological fluids in neovascular age-related degeneration, and it's repeatability using deep learning

In this peer reviewed publication, we develop a reliable algorithm for the automated identification, localization, and volume measurement of exudative manifestations in neovascular age-related macular degeneration (nAMD), including intraretinal (IRF), subretinal fluid (SRF), and pigment epithelium detachment (PED), using a deep-learning approach. The deep-learning algorithm can simultaneously acquire a high level of performance for the identification and volume measurements of IRF, SRF, and PED in nAMD, providing accurate and repeatable predictions. Including layer segmentation during training and squeeze-excite block in the network architecture were shown to boost the performance. Source: Mantel et al. , TVST 2021, 10 (17) - https://doi.org/10.1167/tvst.10.4.17 Authors: Irmela Mantel; Agata Mosinska; Ciara Bergin; Maria Sole Polito; Jacopo Guidotti; Stefanos Apostolopoulos; Carlos Ciller; Sandro De Zanet

Translation Vision Science and Technology

RetinAI receives ISO 13485:2016 certification

Retinai has just received the ISO 13485 certification, a recognition awarded by regulatory bodies and necessary for companies willing to develop & commercialise Medical Devices. RetinAI Discovery, our platform for medical image and data management in ophthalmology, is now getting ready to be commercialised to clinics as a medical device. We are extremely proud of the team for achieving the certification!

Contact us for more informations! We are happy to hear from you!